Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (969)	1/11/1999 11:03:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 1477

So, why you don't ask friend what is his base for positive opinion on Natrecor AC recommendation for approval? I will love to hear his view. IMO, Natrecor do have good chance to be recommended by AC and I did elaborate this my position. However, I didn't exclude possibility that there may be some problem(s), but I do not know what this problems may be. RE: Today news, It is positive for SCIO and bring additional value to their Alzheimer's program. However, one note did leave me disappointed: <<Fiblast® (trafermin) is in Phase II/III clinical trials in Europe for the treatment of stroke and additional Phase II clinical trials in vascular disease are planned.>> So, current data from completed PII trials in vascular diseases are not sufficient for pivotal trial. Chiron does have advantage for now. I am not happy with this. :( Miljenko